Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

BACKGROUND: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increas...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lung Cancer (Auckl)
Hlavní autoři: Sugiura, Yasoo, Nemoto, Etsuo, Kawai, Osamu, Ohkubo, Yasuyuki, Fusegawa, Hisae, Kaseda, Shizuka
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2013
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217440/
https://ncbi.nlm.nih.gov/pubmed/28210130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S45172
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky